NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Persistent Systems Reports Steady Quarter with 3.4% QoQ Growth

Persistent Systems Ltd (PSYS) has delivered a steady quarter, with revenue reaching USD 436mn. The company's revenue growth in constant currency was 3.4% quarter-over-quarter (QoQ), primarily driven by continued strength in the BFSI (Banking, Financial Services, and Insurance) vertical. Additionally, the Healthcare & Life Sciences and Hi-Tech & Emerging verticals also remained supportive, with revenue growth of 11.2% and 14.1% year-over-year (YoY) respectively.

The company's earnings before interest and taxes (EBIT) margin stood at 16.3%, reflecting a decline of approximately 40 basis points (bps) QoQ, adjusted for prior one-offs. Margin pressures were largely attributable to higher consulting, subcontracting, and travel expenses, along with increased spend on software licenses. However, these pressures were partly offset by operational efficiencies and favorable currency movements.

Outlook and Revised Valuation

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Despite resilient execution and strong deal momentum, the combination of softer FY27E commentary and emerging AI-led deflation risks has led to a revision in the company's valuation multiple. The revised valuation multiple is 35x (from 40x), resulting in a revised target price (TP) of ₹6,350 based on FY2028E EPS. Despite this revision, the company maintains its BUY rating.

Revenue Growth Comparison

VerticalQoQ GrowthYoY Growth
BFSI--
Healthcare & Life Sciences-11.2%
Hi-Tech & Emerging-14.1%
Total3.4%-

Investor Takeaway

Investors should consider buying Persistent Systems Ltd due to its strong execution and deal momentum.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.